Skip to main content
. 2022 Sep 8;9:989265. doi: 10.3389/fmed.2022.989265

TABLE 3.

Characteristics of included studies in the narrative synthesis of mortality predictors among PLWH on induction therapy in Africa, 1998–2018.

Author Year Country Sample size Study design % Men Median/mean age Median CD4 cells/mm3 ART history CM diagnosis confirmed by Treatment % death
Luma et al. (37) 2013 Cameroon 672 CS 57.3 36.9 23 No data India Ink/CT Fluconazole 5.8
Patel et al. (4) 2018 Botswana 236 C 69 36 39 57% India Ink/CSF CRAG/CSF Culture Amphotericin, Fluconazole 67.3
Nussbaum et al. (46) 2010 Malawi 41 RCT 66 36 21 All naïve India Ink/CSF CRAG/CSF Culture Fluconazole, Flucytosine 48.8
Kizza et al. (47) 1998 Uganda 58 RCT 47 34 77 No data India Ink/CSF CRAG/SCF Culture Fluconazole, Flucytosine 46.6
Longley et al. (48) 2008 Uganda 60 C 57 34 12 All naïve India Ink/CSF Culture Fluconazole 51.7
Lightowler et al. (49) 2010 South Africa 186 CSe 49.5 32 36 14.5% CSF Culture/India ink Amphotericin, Fluconazole 33.9
Gaskell et al. (50) 2014 Malawi 58 C 51 35 36 45% India Ink. CSF Culture Fluconazole 44.9
Hiesgen et al. (51) 2017 South Africa 87 C 55.2 34 52 44.8% India Ink/CSF CRAG/CSF Culture Amphotericin, Fluconazole 31
Bicanic et al. (52) 2009 Thailand, South Africa, Uganda 262 C 45 33 26 No data CSF Culture Amphotericin, Fluconazole, Flucytosine 31

CSF, cerebral spinal fluid; CRAG, Cryptococcal antigen; ART, antiretroviral therapy; CD4, cluster of differentiation 4; CM, cryptococcal meningitis; CT, computerized tomography scan; CSF, cerebral spinal fluid;%, percentage; CS, Cross-sectional; C, Cohort; RCT, Randomized control trial; CSe, Case series.